Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes

被引：13
|
作者：
Yaribeygi, Habib [1 ]
Atkin, Stephen L. [2 ]
Sahebkar, Amirhossein [3 ,4 ,5 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Chron Kidney Dis Res Ctr, Tehran, Iran
[2] Weill Cornell Med Qatar, Doha, Qatar
[3] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran
[4] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran
[5] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran
来源：
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS | 2019年 / 13卷 / 02期
关键词：
Sodium-glucose co-transporter inhibitors; Oxidative stress; Diabetes mellitus; Hypertension; INADEQUATE GLYCEMIC CONTROL; COTRANSPORTER; 2; INHIBITORS; DOUBLE-BLIND; OXIDATIVE STRESS; NITRIC-OXIDE; ADD-ON; GLOMERULAR HYPERFILTRATION; RENAL DYSFUNCTION; NERVOUS-SYSTEM; TYPE-2;
D O I：
10.1016/j.dsx.2019.03.031
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes. (c) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：1679 / 1683
页数：5
相关论文
共 50 条
  • [21] SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (12) : 1879 - 1904
  • [22] Effects of SGLT2 inhibition on lipid storage and lipolysis in adipose tissue in type 2 diabetes
    Lauritsen, K. M.
    Voigt, J. H.
    Pedersen, S. B.
    Hansen, T. K.
    Moller, N.
    Jessen, N.
    Gormsen, L. C.
    Sondergaard, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 107 - 107
  • [23] RENOPROTECTION WITH SGLT2 INHIBITION
    Panchapakesan, U.
    Forbes, J.
    Pegg, K.
    Mudaliar, H.
    Pollock, C.
    Mather, A.
    NEPHROLOGY, 2011, 16 : 33 - 33
  • [24] Effect of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, on Systolic Blood Pressure in Patients with Type 2 Diabetes
    Hardin, Marquette
    Davies, Michael
    Carroll, Amy
    Umpierrez, Guillermo
    CIRCULATION, 2024, 150
  • [25] Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
    Muskiet, Marcel H. A.
    van Bommel, Erik J. M.
    van Raalte, Daniel H.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 188 - 189
  • [26] The relationship between SGLT2 and systemic blood pressure regulation
    Ahwin, Priscilla
    Martinez, Diana
    HYPERTENSION RESEARCH, 2024, 47 (08) : 2094 - 2103
  • [27] Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations
    Bryony Beal
    Aletta E. Schutte
    Brendon L. Neuen
    Current Hypertension Reports, 2023, 25 : 429 - 435
  • [28] Blood pressure goals, variability and SGLT2 blockade in CKD
    Debbie L. Cohen
    Raymond R. Townsend
    Nature Reviews Nephrology, 2017, 13 : 75 - 76
  • [29] Blood pressure goals, variability and SGLT2 blockade in CKD
    Cohen, Debbie L.
    Townsend, Raymond R.
    NATURE REVIEWS NEPHROLOGY, 2017, 13 (02) : 75 - 76
  • [30] Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations
    Beal, Bryony
    Schutte, Aletta E.
    Neuen, Brendon L.
    CURRENT HYPERTENSION REPORTS, 2023, 25 (12) : 429 - 435
12345